BofA lowered the firm’s price target on BioNTech (BNTX) to $126 from $127 and keeps a Buy rating on the shares. BofA remains cautious on the near-term outlook for the COVID-19 franchise and will look for updates in Q2 call and additional color on policy and guideline impacts, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer
- BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment?
- BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment
- BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer
- BioNTech SE’s New Lung Cancer Study: A Potential Game-Changer?